$DYN
Dyne Therapeutics Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020050870 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.840M $2.786M
YoY Change
% of Gross Profit
Research & Development $9.679M $11.04M $2.982M
YoY Change 224.58%
% of Gross Profit
Depreciation & Amortization $200.0K $250.0K $100.0K
YoY Change 100.0%
% of Gross Profit
Operating Expenses $13.52M $13.83M $2.982M
YoY Change 353.39%
Operating Profit -$13.52M -$3.629M
YoY Change 272.55%
Interest Expense -$130.0K $290.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$400.0K -$1.323M -$2.242M
YoY Change -82.16%
Pretax Income -$13.92M -$14.86M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$13.92M -$14.86M -$5.871M
YoY Change 137.1%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$319.3K -$340.9K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $379.6M $14.63M
YoY Change
Cash & Equivalents $379.6M $14.63M $17.77M
Short-Term Investments $0.00
Other Short-Term Assets $200.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $379.8M $14.76M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.441M $1.486M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $191.0K $191.0K
YoY Change
Total Long-Term Assets $1.632M $1.677M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $379.8M $14.76M
Total Long-Term Assets $1.632M $1.677M
Total Assets $381.5M $16.44M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.488M $1.256M
YoY Change
Accrued Expenses $2.700M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.678M $2.358M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $9.936M
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $9.936M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.678M $2.358M
Total Long-Term Liabilities $9.936M
Total Liabilities $14.61M $2.400M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$50.53M -$19.75M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $366.8M $14.04M $19.43M
YoY Change
Total Liabilities & Shareholders Equity $381.5M $16.44M
YoY Change

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$13.92M -$14.86M -$5.871M
YoY Change 137.1%
Depreciation, Depletion And Amortization $200.0K $250.0K $100.0K
YoY Change 100.0%
Cash From Operating Activities -$11.87M -$6.990M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$160.0K -$1.470M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$160.0K -$1.470M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 380.0M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -11.87M -6.990M
Cash From Investing Activities -160.0K -1.470M
Cash From Financing Activities 380.0M 0.000
Net Change In Cash 367.9M -8.460M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$11.87M -$6.990M
Capital Expenditures -$160.0K -$1.470M
Free Cash Flow -$11.71M -$5.520M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1488000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
234000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
127000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
379840000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
14759000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1441000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1486000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
191000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
191000
CY2020Q3 us-gaap Assets
Assets
381472000
CY2019Q4 us-gaap Assets
Assets
16436000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1256000
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3190000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1102000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4678000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2358000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9936000
CY2020Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
13000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
42000
CY2019Q4 us-gaap Liabilities
Liabilities
2400000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50534000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19746000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
366845000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
14036000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
381472000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16436000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
68000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45445115
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3239017
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45004247
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2586535
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9679000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2982000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23102000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6781000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3841000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
647000
us-gaap Operating Expenses
OperatingExpenses
30047000
us-gaap Operating Expenses
OperatingExpenses
8356000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13520000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3629000
us-gaap Interest Income Other
InterestIncomeOther
223000
CY2020Q3 us-gaap Interest Expense Other
InterestExpenseOther
130000
us-gaap Interest Expense Other
InterestExpenseOther
315000
CY2019Q3 dyn Changes In Fair Value Of Preferred Stock Tranche Obligations
ChangesInFairValueOfPreferredStockTrancheObligations
2352000
dyn Changes In Fair Value Of Preferred Stock Tranche Obligations
ChangesInFairValueOfPreferredStockTrancheObligations
1323000
CY2020Q3 dyn Changes In Success Fee Obligation
ChangesInSuccessFeeObligation
270000
dyn Changes In Success Fee Obligation
ChangesInSuccessFeeObligation
450000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-400000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2242000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-741000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1100000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-13920000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5871000
us-gaap Net Income Loss
NetIncomeLoss
-30788000
us-gaap Net Income Loss
NetIncomeLoss
-9456000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.01
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.94
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6920008
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2491487
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4100504
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2401039
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
66000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7886000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
8188000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8982000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-719000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
246411000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2235000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-4879000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2087000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-6964000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1497000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-8457000
CY2019Q3 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
33748000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
19427000
us-gaap Profit Loss
ProfitLoss
-30788000
us-gaap Profit Loss
ProfitLoss
-9456000
us-gaap Share Based Compensation
ShareBasedCompensation
2376000
us-gaap Share Based Compensation
ShareBasedCompensation
12000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
483000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
125000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
107000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
329000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1114000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
505000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26472000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7820000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
438000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
910000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-438000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-910000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
247454000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9936000
dyn Payments For Settlement Of Success Fee Obligation
PaymentsForSettlementOfSuccessFeeObligation
450000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
134920000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
19989000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
391884000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19989000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
364974000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11259000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14632000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6508000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
379606000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17767000
dyn Cash Paid For Interest And Income Taxes
CashPaidForInterestAndIncomeTaxes
311000
dyn Reclassification Of Preferred Stock Tranche Obligation Liability To Permanent Equity
ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity
6319000
dyn Settlement Of Tranche Right One
SettlementOfTrancheRightOne
1621000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
162215000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
370000
dyn Issuance Costs From Convertible Preferred Stock Included In Accounts Payable Or Accrued Expenses
IssuanceCostsFromConvertiblePreferredStockIncludedInAccountsPayableOrAccruedExpenses
134000
dyn Public Offering Costs Included In Accounts Payable Or Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableOrAccruedExpenses
1043000
CY2020Q3 dyn Success Fee Paid
SuccessFeePaid
500000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2219000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;;font-style:italic;font-weight:bold;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-14900000
CY2019Q4 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2019Q4 dyn Fair Value Liabilities Transfers Amount
FairValueLiabilitiesTransfersAmount
0
CY2020Q3 dyn Fair Value Liability Payment Percentage
FairValueLiabilityPaymentPercentage
1.00
CY2020Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
500000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1781000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
778000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
295000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
CY2019Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1318000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
540000
CY2020Q3 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
23000
CY2019Q4 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
60000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
458000
CY2020Q3 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
818000
CY2019Q4 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
484000
CY2020Q3 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
36000
CY2019Q4 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
18000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
537000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0146
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0167
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.025
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
311303
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6167369
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
30409
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
110484
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6337779
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
82768
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6337779
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.93
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.94
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.82
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.04
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.78
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.97
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.78
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
589000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
84984000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1591000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
84984000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.27
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2235000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2376000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7153784
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10840004
dyn Lease Executed Date
LeaseExecutedDate
2019-07-01
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-12-31
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
197000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
800000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
997000

Files In Submission

Name View Source Status
0001564590-20-050870-index-headers.html Edgar Link pending
0001564590-20-050870-index.html Edgar Link pending
0001564590-20-050870.txt Edgar Link pending
0001564590-20-050870-xbrl.zip Edgar Link pending
dyn-10q_20200930.htm Edgar Link pending
dyn-20200930.xml Edgar Link completed
dyn-20200930.xsd Edgar Link pending
dyn-20200930_cal.xml Edgar Link unprocessable
dyn-20200930_def.xml Edgar Link unprocessable
dyn-20200930_lab.xml Edgar Link unprocessable
dyn-20200930_pre.xml Edgar Link unprocessable
dyn-ex311_6.htm Edgar Link pending
dyn-ex312_7.htm Edgar Link pending
dyn-ex321_8.htm Edgar Link pending
dyn-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending